-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Deepening Our Commitment to the Pharmaceutical Industry and Increasing Investment in Technology — An Interview with Sun Lijie, Executive President and General Manager of the R&D Center at Shijiazhuang Sihua Pharmaceutical Co., Ltd.
Category:
发布时间：2022-05-21
【概要描述】
“As a high-level talent in science, technology, and innovation entrepreneurship in Shijiazhuang City, I have received financial and policy support from the Municipal Party Committee and the Municipal Government, enabling me to conduct in-depth research on key technologies in the pharmaceutical field and achieve groundbreaking results,” said Sun Lijie, Executive President of Shijiazhuang No. 4 Pharmaceutical Co., Ltd. and General Manager of its R&D Center, when discussing the city’s talent policies.
“As a high-level innovation and entrepreneurship talent in Shijiazhuang, I have received financial and policy support from the Municipal Party Committee and the Municipal Government, enabling me to conduct in-depth research on key technologies in the pharmaceutical field and achieve groundbreaking results,” said Sun Lijie, Executive President of Shijiazhuang No. 4 Pharmaceutical Co., Ltd. and General Manager of its R&D Center, when discussing the city’s talent policies.
Building on the recognition of our city’s talent policies, Sun Lijie led his company’s team in focusing on innovative R&D mechanisms, strengthening research and development on major projects, breaking down technical barriers, and developing highly innovative, high-value-added products for the enterprise. He spearheaded the research and development of a quality-control system for soft packaging of large-volume infusions, which was subsequently established and put into practical application, earning the First Prize for Scientific and Technological Progress from Hebei Province and being integrated into actual drug-development efforts.
Sun Lijie has led his team in collaborating with academician-led research groups, Tianjin University, Tsinghua University, China Pharmaceutical University, and other cutting-edge institutions to develop innovative drugs, striving to drive the company’s transformation and upgrading and propel it into the forefront of domestic pharmaceutical R&D. Currently, multiple Class 1 new drug candidates are under development, among which the innovative drug ADN-9 holds promise to fill the therapeutic gap in liver fibrosis treatment. At the same time, the company is advancing the development of novel formulation technologies, partnering with research institutes to create long-acting, targeted formulations such as microspheres, micronized crystals, and liposomal drugs.
“Following the implementation of the government’s talent-support policies, our company has placed even greater emphasis on talent development,” said Sun Lijie. “Leveraging existing talent-development platforms—such as key collaborative institutions with academicians, postdoctoral workstations, and Nobel Prize–affiliated research stations—we have cultivated 102 high-level professionals and recruited more than ten doctoral degree holders.”
Our city’s biopharmaceutical industry is thriving. Under the leadership of Sun Lijie, the company has deepened its commitment to the pharmaceutical sector. Building on its existing technological innovations, the company has further enhanced its R&D investment, strengthened its talent pool, and integrated and optimized its scientific and technological resources, thereby continuously elevating its innovation capabilities and core competitiveness and developing more and better medicines. At the same time, Sun Lijie stated that the company will continue to increase its R&D spending and invest in talent development, leveraging our city’s favorable talent policies to attract and cultivate top talent for the pharmaceutical industry.
Reposted from: “ Shijiazhuang Daily 》
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091